SCHEMBL6740765

SCHEMBL6740765

Cc1ccc2c(cc(C(=O)O)n2CCCC#N)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.42
CNR2 P34972 3/20 0.41
SYK P43405 2/20 0.38
MCL1 Q07820 3/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CCR2 P41597 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MAPK1 P28482 1/20 0.35
STAT3 P40763 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
APEX1 P27695 1/20 0.34
RECQL P46063 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
POLB P06746 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27542798 0.78 RAB9A (0.54) RAB9AKDM4EALDH1A1HPGDPOLB
SCHEMBL28004668 0.74 CNR2 (0.47) CNR2ALDH1A1CCR2POLBCYP1A2
SCHEMBL28112083 0.74 CNR2 (0.68) CNR2MCL1ALDH1A1CCR2POLB
SCHEMBL15649683 0.73 CCR2 (0.58) CNR2MCL1CCR2
SCHEMBL6703577 0.73 HSD17B10 (0.48) KDM4EALDH1A1CCR2HSD17B10
SCHEMBL19687591 0.69 MEN1 (0.43) RAB9AKDM4EESR1ESR2
SCHEMBL8417551 0.68 FABP4 (0.56) MCL1KDM4EALDH1A1HSD17B10POLB
SCHEMBL4024245 0.67 FABP4 (0.50) KDM4EALDH1A1HSD17B10GLAHPGD
SCHEMBL19687581 0.66 KDM4E (0.44) RAB9AKDM4EALDH1A1HSD17B10MAPK1
SCHEMBL6703370 0.65 F10 (0.51) ALDH1A1CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043995-A1 Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them BIGNON ERIC (FR) 2004-03-04 US disclosed
EP-0984960-B1 N-TRIAZOLYL-2-INDOLECARBOXAMIDES AND THEIR USE AS CCK-A AGONISTS SANOFI SYNTHELABO (FR) 2003-02-05 EP disclosed
CN-1263528-A N-triazolyl-2-indolecarboxamides and their use in CCK-A agonists SANOFI SYNTHELABO (FR) 2000-08-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043995-A1 Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them CCKAR, CCKBR, NPY1R RAB9A 1127/4885CNR2 73/4885SYK 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.